

Viread® (tenofovir disoproxil fumarate) Crushing or Splitting of Tablets

This document is in response to your request for information regarding splitting or crushing Viread® (tenofovir disoproxil fumarate [TDF]) tablets.

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

The full indication, important safety information, and boxed warnings are available at: www.gilead.com/-/media/files/pdfs/medicines/hiv/viread/viread_pi.

Product Labeling¹

There is no information in the TDF US Product Information about the crushing or splitting of TDF tablets; therefore, it is not recommended that TDF be administered as a crushed or split tablet.

TDF has a solubility of 13.4 mg/mL in distilled water at 25°C.

TDF is also available as an oral powder. Please refer to the US product labeling for information regarding the preparation and administration of TDF oral powder.

Clinical Data on Crushing or Splitting TDF Tablets

Gilead Data

TDF tablets are not enteric-coated and do not possess a sustained-release mechanism. TDF tablets can be disintegrated in at least 100 mL of water, orange juice, or grape juice with minor stirring and pressure with a spoon.² Currently, there are no studies evaluating the PK (eg, oral bioavailability) of a crushed TDF tablet dispersed into a liquid medium (eg, milk, water, juice) compared with a whole tablet.

Similarly, splitting TDF tablets has not been studied, and it is not recommended. Currently, there are no studies evaluating the PK of a split tablet versus a whole tablet.

Non-Gilead Data

A literature search was conducted in Ovid MEDLINE and Embase databases for studies published up to January 15, 2026, using the search terms Viread, tenofovir disoproxil fumarate, cutting, crushing, and splitting tablets, and related search terms. The information presented below was found.

Case reports

There are limitations in the interpretation of case reports. Case reports cannot be generalized. Unlike controlled clinical trials, causality cannot be inferred based on uncontrolled observational data. Additionally, incidence or prevalence cannot be estimated due to the lack of a representative population sample. Other limitations of case reports include the retrospective design and publication bias.³

Crushed TDF administered via PEG tube in the setting of infection⁴

A 44-year-old, Caucasian male with HIV presented with relapsing, life-threatening toxoplasma encephalitis and other recurring opportunistic infections. He was chronically non-adherent to oral ARVs, which resulted in critical illness, suppressed CD4 lymphocyte count, and an elevated HIV RNA viral load. A previous phenotypic resistance test showed resistance to 3TC and all NNRTIs but susceptibility to all available PIs and all other NRTIs. A PEG tube was inserted after failed attempts to overcome physiological aversion to taking medication orally and to begin treatment for an opportunistic infection. An ARV regimen of liquid formulations of LPV, low-dose RTV, ABC, TDF, 3TC, and subcutaneous T20 was initiated. The patient used his PEG tube over the entire 15-month follow-up period, and he maintained virologic suppression (HIV RNA <50 c/mL).

Crushed TDF administered via PEG tube in setting of oral candidiasis⁵

A 40-year-old, White female presented with late-stage HIV disease, a nadir absolute CD4 lymphocyte count of 10 cells/mm³, HIV-related wasting, and azole-resistant oral-esophageal candidiasis. The patient failed multiple ARV regimens due to tolerability issues, including difficulty swallowing capsules and taste aversions to liquids, which led to her provider's decision to perform a PEG tube placement for ARV administration. The patient was started on a regimen that included APV; however, a moderate-to-severe, generalized, erythematous, and pruritic maculopapular eruption rash occurred after two attempts at APV initiation. Due to limited treatment options, APV desensitization was performed and administered via a PEG tube. Desensitization was successful, and she started the following medications via PEG tube: RTV oral solution 100 mg twice daily, a crushed 300 mg tablet of TDF once daily, and 3TC oral solution 300 mg once daily. The regimen was continued for more than 19 months without another rash or other indications of hypersensitivity. For the first 6 months after starting this regimen, the patient responded well with a decline in HIV RNA and an increase in CD4 cell count. However, she eventually had signs of treatment failure, which resulted in T20 initiation. She responded well to the new treatment agent, with a 15-lb weight gain, an increase in CD4 count to 159 cells/mm³, and a decrease in HIV RNA viral load to 11,800 c/mL, and she remained free of opportunistic infections.

Crushed TDF administered in pediatric patient via gastrostomy tubes⁶

A study was conducted to evaluate the PK of NNRTIs and PIs in children with gastrostomy tubes. One patient received TDF as part of their regimen, but PK results specific to TDF or general efficacy outcomes were not available for this patient.

References

1. Enclosed. Gilead Sciences Inc, VIREAD® (tenofovir disoproxil fumarate) tablets, for oral use/ VIREAD® (tenofovir disoproxil fumarate) powder, for oral use. U.S. Prescribing Information. Foster City, CA.
2. Gilead Sciences Inc. Data on File.
3. Nissen T, Wynn R. The Clinical Case Report: A Review of Its Merits and Limitations. *BMC Res Notes*. 2014;7:264. <https://www.ncbi.nlm.nih.gov/pubmed/24758689>
4. Leipe J, Hueber AJ, Rech J, Harrer T. Bypassing non-adherence via PEG in a critically ill HIV-1-infected patient. *AIDS Care*. 2008;20(7):863-867.
5. Kohli-Pamnani A, Huynh P, Lobo F. Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus. *Ann Allergy Asthma Immunol*. 2006;96(4):620-623.
6. King JR, Yoge R, Aldrovandi G, Chadwick E, Acosta EP. Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube. *HIV Clin Trials*. 2004;5(5):288-293.

Abbreviations

3TC=lamivudine

ABC=abacavir

APV=amprenavir

ARV=antiretroviral

CD4=cluster of differentiation 4

c/mL=copies/mL

LPV=lopinavir

NNRTI=non-nucleos(t)ide

reverse transcriptase

inhibitor

NRTI=nucleos(t)ide reverse transcriptase inhibitor

PEG=percutaneous endoscopic gastrostomy

PI=protease inhibitor

PK=pharmacokinetic(s)

RTV=ritonavir

T20=enfuvirtide

TDF=tenofovir disoproxil fumarate

Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Viread US Prescribing Information available at:

www.gilead.com/-/media/files/pdfs/medicines/hiv/viread/viread_pi.

Follow-Up

For any additional questions, please contact Gilead Medical Information at:

✉ 1-866-MEDI-GSI (1-866-633-4474) or ✉ www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or
✉ www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉ MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or ✉ www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact privacy@gilead.com.

VIREAD, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

© 2026 Gilead Sciences, Inc.